ERBB2 and neoplasm: The cytotoxicity of Zapadcine-1 to all the tumor cells tested is much stronger than the controls of naked monoclonal antibody Zaptuzumab and the non-targeted ADC, anti-HER-2 ADC of hertuzumab-MC-VC-PAB-MMAE (Figure 3).